Skip to main content
Smart Investors Daily
ArriVent BioPharma, Inc. Common Stock logo

NASDAQ · AVBP

ArriVent BioPharma, Inc. Common Stock

Healthcare · Biotechnology

$10.90

Up+$0.36 (+3.30%)

Updated Nov 20, 2026, 1:10 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.01B
P/E ratio
-6.23
Dividend yield
0.00%
52-week range
$10.33 – $35.83
Volume
2.7M
Avg. volume
349.38K

Price performance · AVBP

AVBP price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

AVBP closed at $10.90 after 20 trading sessions, down 43.23% for the selected period.

Last close
$10.90
Period change
-43.23%
Period low
$10.69
Period high
$21.00
Daily close
View OHLC price history
AVBP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$10.44$11.11$10.33$10.902.7M
Nov 17, 2026$11.57$11.87$10.495$10.69863.86K
Nov 16, 2026$12.86$13.142$11.55$11.56644.24K
Nov 13, 2026$13.00$13.24$12.592$13.01616.14K
Nov 12, 2026$13.55$13.62$12.89$13.07793.95K
Nov 11, 2026$13.62$13.91$13.38$13.505911.26K
Nov 10, 2026$14.25$15.05$13.21$13.49776.3K
Nov 9, 2026$13.86$14.595$13.49$14.16905.97K
Nov 6, 2026$12.40$13.875$12.00$13.641.4M
Nov 5, 2026$13.39$13.50$12.18$12.231.1M
Nov 4, 2026$13.39$13.57$12.465$13.491.86M
Nov 3, 2026$13.47$13.96$13.01$13.021.23M
Nov 2, 2026$14.89$14.99$13.255$13.351.24M
Oct 30, 2026$15.78$16.165$14.325$14.871.19M
Oct 29, 2026$15.87$16.42$15.73$15.95658.31K
Oct 28, 2026$15.67$15.885$15.20$15.73990K
Oct 27, 2026$15.45$15.69$15.00$15.401.58M
Oct 26, 2026$18.14$18.16$14.78$15.365.95M
Oct 23, 2026$19.00$21.23$18.18$21.003.28M
Oct 22, 2026$18.93$19.68$18.78$19.20843.7K

Latest AVBP news

The latest Smart Investors Daily articles mentioning AVBP.

AVBP research

Overview

Company profile and research snapshot.

Company profile

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$40.33
Implied upside
—
Analysts
—
AVBP recent ratings
DateFirmRatingTarget
Nov 16, 2026GuggenheimBuy—
Nov 10, 2026Truist SecuritiesBuy—
Oct 27, 2026GuggenheimBuy—
Oct 20, 2026B. Riley SecuritiesBuy—
Oct 16, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 9, 2026

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLCPresented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMODosed first patient in U.S. Phase 1a/1b study of ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC, with initial focus in ovarian and endometrial cancersStrengthened clinical leadership with announcement of Priti Patel, M.D., M.S., as Chief Medical Officer, bringing extensive oncology development exper

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.